Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 18 studies | 44% ± 16% | |
peripheral blood | 18 studies | 36% ± 11% | |
brain | 14 studies | 30% ± 11% | |
intestine | 12 studies | 32% ± 17% | |
eye | 10 studies | 34% ± 16% | |
kidney | 9 studies | 41% ± 10% | |
liver | 7 studies | 38% ± 25% | |
lymph node | 6 studies | 36% ± 15% | |
pancreas | 5 studies | 49% ± 21% | |
uterus | 5 studies | 43% ± 20% | |
placenta | 4 studies | 57% ± 26% | |
bone marrow | 4 studies | 38% ± 14% | |
prostate | 4 studies | 27% ± 9% | |
breast | 4 studies | 37% ± 5% | |
heart | 3 studies | 28% ± 9% | |
adrenal gland | 3 studies | 33% ± 8% | |
esophagus | 3 studies | 49% ± 29% | |
skin | 3 studies | 36% ± 10% | |
thymus | 3 studies | 59% ± 25% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 1973.33 | 21 / 21 | 100% | 64.45 | 504 / 504 |
breast | 100% | 2190.03 | 459 / 459 | 100% | 63.65 | 1118 / 1118 |
esophagus | 100% | 2240.25 | 1445 / 1445 | 100% | 46.67 | 183 / 183 |
kidney | 100% | 2263.29 | 89 / 89 | 100% | 47.08 | 901 / 901 |
liver | 100% | 1154.93 | 226 / 226 | 100% | 37.30 | 406 / 406 |
ovary | 100% | 1479.69 | 180 / 180 | 100% | 51.89 | 430 / 430 |
prostate | 100% | 1972.70 | 245 / 245 | 100% | 59.35 | 502 / 502 |
skin | 100% | 2609.19 | 1809 / 1809 | 100% | 67.34 | 472 / 472 |
stomach | 100% | 1629.30 | 359 / 359 | 100% | 43.82 | 286 / 286 |
thymus | 100% | 2222.92 | 653 / 653 | 100% | 65.64 | 605 / 605 |
uterus | 100% | 1952.09 | 170 / 170 | 100% | 80.20 | 459 / 459 |
brain | 100% | 2854.93 | 2641 / 2642 | 100% | 67.17 | 705 / 705 |
lung | 100% | 2215.46 | 577 / 578 | 100% | 64.25 | 1155 / 1155 |
intestine | 100% | 1963.96 | 966 / 966 | 100% | 47.56 | 526 / 527 |
adrenal gland | 100% | 2435.94 | 258 / 258 | 100% | 53.91 | 229 / 230 |
pancreas | 96% | 757.75 | 314 / 328 | 99% | 53.36 | 177 / 178 |
adipose | 100% | 2107.60 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 43.36 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 110.93 | 29 / 29 |
spleen | 100% | 2247.88 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 71.18 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 66.48 | 1 / 1 |
blood vessel | 100% | 2088.15 | 1334 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 2525.71 | 802 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 2283.66 | 854 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 92% | 1927.02 | 851 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0031146 | Biological process | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process |
GO_0016567 | Biological process | protein ubiquitination |
GO_0062197 | Biological process | cellular response to chemical stress |
GO_0006281 | Biological process | DNA repair |
GO_0007283 | Biological process | spermatogenesis |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0000165 | Biological process | MAPK cascade |
GO_0034644 | Biological process | cellular response to UV |
GO_0032436 | Biological process | positive regulation of proteasomal ubiquitin-dependent protein catabolic process |
GO_0006974 | Biological process | DNA damage response |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_1902883 | Biological process | negative regulation of response to oxidative stress |
GO_0140627 | Biological process | ubiquitin-dependent protein catabolic process via the C-end degron rule pathway |
GO_0043687 | Biological process | post-translational protein modification |
GO_0090090 | Biological process | negative regulation of canonical Wnt signaling pathway |
GO_0032480 | Biological process | negative regulation of type I interferon production |
GO_0045732 | Biological process | positive regulation of protein catabolic process |
GO_0070936 | Biological process | protein K48-linked ubiquitination |
GO_0045116 | Biological process | protein neddylation |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0071230 | Biological process | cellular response to amino acid stimulus |
GO_1902499 | Biological process | positive regulation of protein autoubiquitination |
GO_0006513 | Biological process | protein monoubiquitination |
GO_1904263 | Biological process | positive regulation of TORC1 signaling |
GO_1900076 | Biological process | regulation of cellular response to insulin stimulus |
GO_0042110 | Biological process | T cell activation |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0031464 | Cellular component | Cul4A-RING E3 ubiquitin ligase complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0031463 | Cellular component | Cul3-RING ubiquitin ligase complex |
GO_0031466 | Cellular component | Cul5-RING ubiquitin ligase complex |
GO_0005829 | Cellular component | cytosol |
GO_0031462 | Cellular component | Cul2-RING ubiquitin ligase complex |
GO_0031465 | Cellular component | Cul4B-RING E3 ubiquitin ligase complex |
GO_0031461 | Cellular component | cullin-RING ubiquitin ligase complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0019005 | Cellular component | SCF ubiquitin ligase complex |
GO_0031467 | Cellular component | Cul7-RING ubiquitin ligase complex |
GO_0005634 | Cellular component | nucleus |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0060090 | Molecular function | molecular adaptor activity |
GO_0034450 | Molecular function | ubiquitin-ubiquitin ligase activity |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0061663 | Molecular function | NEDD8 ligase activity |
GO_0097602 | Molecular function | cullin family protein binding |
GO_0061629 | Molecular function | RNA polymerase II-specific DNA-binding transcription factor binding |
GO_0019788 | Molecular function | NEDD8 transferase activity |
GO_0008270 | Molecular function | zinc ion binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | RBX1 |
Protein name | E3 ubiquitin-protein ligase RBX1 (EC 2.3.2.27) (EC 2.3.2.32) (E3 ubiquitin-protein transferase RBX1) (Protein ZYP) (RING finger protein 75) (RING-box protein 1) (Rbx1) (Regulator of cullins 1) (ROC1) [Cleaved into: E3 ubiquitin-protein ligase RBX1, N-terminally processed (E3 ubiquitin-protein transferase RBX1, N-terminally processed)] |
Synonyms | ROC1 RNF75 |
Description | FUNCTION: E3 ubiquitin ligase component of multiple cullin-RING-based E3 ubiquitin-protein ligase (CRLs) complexes which mediate the ubiquitination and subsequent proteasomal degradation of target proteins, including proteins involved in cell cycle progression, signal transduction, transcription and transcription-coupled nucleotide excision repair . CRLs complexes and ARIH1 collaborate in tandem to mediate ubiquitination of target proteins, ARIH1 mediating addition of the first ubiquitin on CRLs targets . The functional specificity of the E3 ubiquitin-protein ligase complexes depends on the variable substrate recognition components. As a component of the CSA complex promotes the ubiquitination of ERCC6 resulting in proteasomal degradation. Recruits the E2 ubiquitin-conjugating enzyme CDC34 to the complex and brings it into close proximity to the substrate. Probably also stimulates CDC34 autoubiquitination. May be required for histone H3 and histone H4 ubiquitination in response to ultraviolet and for subsequent DNA repair. Promotes the neddylation of CUL1, CUL2, CUL4 and CUL4 via its interaction with UBE2M. Involved in the ubiquitination of KEAP1, ENC1 and KLHL41. In concert with ATF2 and CUL3, promotes degradation of KAT5 thereby attenuating its ability to acetylate and activate ATM. As part of a multisubunit complex composed of elongin BC complex (ELOB and ELOC), elongin A/ELOA, RBX1 and CUL5; polyubiquitinates monoubiquitinated POLR2A . . |
Accessions | ENST00000216225.9 P62877 |